---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-22-000073"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:04:52.117355+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Angion Biomedica gets Nasdaq bid-price deficiency notice; 180 days to cure

## Summary
- Received Nasdaq notice on Dec 15, 2022 for common stock closing below $1.00 for 30 consecutive business days.
- Has until June 13, 2023 to regain compliance with minimum $1.00 closing bid for at least 10 consecutive days.
- Company says notification will not adversely impact its ongoing strategic realignment process.
- If not compliant by deadline, may qualify for an additional 180-day period and consider a reverse stock split.
- Currently meets all other Nasdaq listing standards except the bid price requirement.

## SEC filing metadata
- accession: 0001601485-22-000073
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000073/0001601485-22-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000073/angn-20221215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-22-000073
- JSON: https://secwatch.observer/filing/0001601485-22-000073.json
- Plain text: https://secwatch.observer/filing/0001601485-22-000073.txt

## Key facts
- Listing & Compliance Notices
  Elicio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: December 15, 2022, Angion Biomedica Corp. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of Angion ’s common stock on Nasdaq and Angion does not believe the notification will adversely impact its ongoing strategic realignment process, previous
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000073/0001601485-22-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.